UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Enrolling By Invitation
99 years or below
All
25 participants needed
1 Location

Brief description of study

TBD

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: solid tumor, cancer
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 828778
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

 

Interested in the study?

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact a study center.